L. Mellars

2.6k total citations · 1 hit paper
12 papers, 2.1k citations indexed

About

L. Mellars is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Immunology. According to data from OpenAlex, L. Mellars has authored 12 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Surgery, 4 papers in Cardiology and Cardiovascular Medicine and 4 papers in Immunology. Recurrent topics in L. Mellars's work include Psoriasis: Treatment and Pathogenesis (4 papers), Synthesis of β-Lactam Compounds (3 papers) and Antiplatelet Therapy and Cardiovascular Diseases (3 papers). L. Mellars is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (4 papers), Synthesis of β-Lactam Compounds (3 papers) and Antiplatelet Therapy and Cardiovascular Diseases (3 papers). L. Mellars collaborates with scholars based in United States, Germany and United Kingdom. L. Mellars's co-authors include Craig Tendler, Leila Alland, D G Kieback, F. Orlandi, Moshe Inbar, Piotr Tomczak, Armando Santoro, Nely Wigler, Eva‐Maria Grischke and Raphael Catane and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Annals of the Rheumatic Diseases.

In The Last Decade

L. Mellars

12 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

2004 1.3k citations E O’Brien, Nely Wigler et al. Annals of Oncology profile →

Peers

Countries citing papers authored by L. Mellars

Since Specialization

Citations

This map shows the geographic impact of L. Mellars's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Mellars with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Mellars more than expected).

Fields of papers citing papers by L. Mellars

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Mellars. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Mellars. The network helps show where L. Mellars may publish in the future.

Co-authorship network of co-authors of L. Mellars

This figure shows the co-authorship network connecting the top 25 collaborators of L. Mellars. A scholar is included among the top collaborators of L. Mellars based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Mellars. L. Mellars is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study 2020 ·Journal of the European Academy of Dermatology and Venereology ·Matthias Augustin, C. Elise Kleyn, Curdin Conrad, Paul Sator, Mona Ståhle, Kilian Eyerich, (unknown), Christine Bundy, L. Mellars, Chiara Greggio, Myriam Cordey, (unknown), C.E.M. Griffiths	24
2	AB0773 PSORIATIC ARTHRITIS IMPACT OF DISEASE QUESTIONNAIRE SCORES ARE CORRELATED WITH DISEASE ACTIVITY, AS MEASURED BY CDAPSA, IN PATIENTS WITH PSORIATIC ARTHRITIS 2019 ·Annals of the Rheumatic Diseases ·Ana‐Maria Orbai, Klaus Krueger, Frank Behrens, Uta Kiltz, B. Guérette, L. Mellars, Michèle Brunori, J. Wollenhaupt	1
3	Real-world burden of comorbidities in US patients with psoriasis 2017 ·Journal of the American Academy of Dermatology ·K. Shah, L. Mellars, Arun Changolkar, Steven R. Feldman	66
4	Real-world burden of comorbidities in US patients with psoriatic arthritis 2017 ·RMD Open ·K. Shah, Maria Paris, L. Mellars, Arun Changolkar, Philip J. Mease	54
5	Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer breakdown → 2004 ·Annals of Oncology ·E O’Brien, Nely Wigler, Moshe Inbar, R. Rosso, Eva‐Maria Grischke, Armando Santoro, Raphael Catane, D G Kieback, Piotr Tomczak, Stephen P. Ackland, F. Orlandi, L. Mellars, Leila Alland, Craig Tendler	1311
6	Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer 2004 ·Journal of Clinical Oncology ·Alan Keller, Robert Mennel, (unknown), (unknown), Aura Erazo, Aňa Lluch, Charles L. Vogel, Manfred Kaufmann, (unknown), I. Craig Henderson, L. Mellars, Leila Alland, Craig Tendler	168
7	Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin 2002 ·British Journal of Clinical Pharmacology ·Teddy Kosoglou, Ingo Meyer, Enrico P. Veltri, Paul Statkevich, Bo Yang, Yali Zhu, L. Mellars, Stephen E. Maxwell, James E. Patrick, David L. Cutler, Vijay Batra, Melton B. Affrime	91
8	The Plasma Concentration and LDL-C Relationship in Patients Receiving Ezetimibe 2001 ·The Journal of Clinical Pharmacology ·Farkad Ezzet, David Wexler, Paul Statkevich, Teddy Kosoglou, James E. Patrick, Leslie Lipka, L. Mellars, Enrico P. Veltri, Vishal Batra	49
9	Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies 2001 ·Clinical Therapeutics ·Harold Bays, Paul B. Moore, Margaret Drehobl, Sidney Rosenblatt, Phillip D. Toth, Carlos A. Dujovne, Robert H. Knopp, Leslie Lipka, Alexandre LeBeaut, Bo Yang, L. Mellars, (unknown), Enrico P. Veltri	253
10	The Plasma Concentration and LDL‐C Relationship in Patients Receiving Ezetimibe 2001 ·The Journal of Clinical Pharmacology ·Farkad Ezzet, David Wexler, Paul Statkevich, Teddy Kosoglou, James E. Patrick, Leslie Lipka, L. Mellars, Enrico P. Veltri, Vishal Batra	6
11	Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin 2000 ·Atherosclerosis ·Teddy Kosoglou, Ingo Meyer, (unknown), L. Mellars, Paul Statkevich, Myron Miller, Paresh Soni, M B Affrime	32
12	Analysis of 24-hour blood pressure data 1996 ·Journal of Biopharmaceutical Statistics ·Bruce E. Rodda, Gerald Hajian, (unknown), L. Mellars, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact